Colgate-Palmolive Company
—- Market cap
- $70.07B
- Debt
- —
- Cash
- −$1.29B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: CL stock price at discount vs ABBV $87.90 current versus $284.17 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABBV's multiple
Implied fair value · at CL's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 87% equity / 13% debt · EV / Revenue 8.35x · EV proxy / EBITDA proxy 21.99x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
COLGATE-PALMOLIVE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CL vs PG
JOHNSON & JOHNSON
CL vs JNJ
CHURCH & DWIGHT CO INC /DE/
CL vs CHD
KIMBERLY CLARK CORP
CL vs KMB
EDGEWELL PERSONAL CARE Co
CL vs EPC
UNILEVER PLC
CL vs UL
Pfizer Inc.
CL vs PFE
Merck & Co., Inc.
CL vs MRK
Eli Lilly and Company
CL vs LLY
Amgen Inc.
CL vs AMGN
Gilead Sciences, Inc.
CL vs GILD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CL can reaccelerate growth while sustaining its high ROIC and stable margins, then holding or accumulating makes sense because the stock is cheaper than ABBV on P/E and P/S but already screens above its historical band and far above the DCF range.
CL trades at a clear discount to ABBV on earnings and sales multiples, but the gap is not uniformly compelling because EV/EBITDA is nearly similar. The current price of $85.10 sits above the top of the historical band and far above the DCF range, which argues that the stock is not obviously cheap on an absolute basis.
Supporting Metrics